VTRS Chart

1 Month

	Date	Diff
	2025-04-24	+2.82 %
Viatris (VTRS) stock rose by 2.82% as investors may be reacting positively to the upcoming deadline for filing lead plaintiff applications in a securities class action lawsuit, which could incentivize purchasing or positioning in the stock ahead of potential legal developments. Viatris (VTRS) stock rose by 2.82% possibly as investors reacted positively amidst news of a class action securities lawsuit addressing previous equity losses, offering a chance for compensation without costs to participants.
	2025-04-23	+1.56 %
Viatris (VTRS) stock rose by 1.56% likely due to positive sentiment surrounding the company's strong performance in new product revenues and its ranking among popular investment picks in the healthcare sector, especially as analysts maintain a bullish outlook on the stock. Viatris (VTRS) stock rose by 1.56% amid ongoing concerns about a class action lawsuit tied to the company's previous disclosures regarding an FDA inspection and its financial impacts; investor sentiment may have improved due to potential positivity surrounding the upcoming legal proceedings. The article discusses a potential class action lawsuit against Viatris (VTRS) after the company's disappointing financial guidance due to issues with its Indore facility; however, Viatris's stock rose by 1.56% likely due to investor optimism about resolving legal concerns and stabilization following a sharp previous decline. The article discusses Viatris Inc. (VTRS) and a class action notice for shareholders regarding allegations of misleading statements related to the company's facility inspections, which previously led to a significant drop in stock price; despite this context, VTRS stock rose by 1.56% likely due to investors responding to potential recovery strategies or optimism about future developments related to the litigation. Viatris (VTRS) stock increased by 1.56% as it is highlighted in discussions about potential investments among affordable stocks under $10, raising investor interest in its value proposition.
	2025-04-21	+0.13 %
Viatris (VTRS) stock was up 0.13% amid news of a lawsuit filed against the company for potential securities law violations, linked to the negative impacts of a failed FDA inspection that severely affected its operations and financial outlook. The stock's slight increase may reflect a temporary market response or investor sentiment amidst ongoing legal proceedings rather than a fundamental improvement in the company's financial health. The article reports that Viatris (VTRS) stock increased by 0.13% despite the announcement of a class action lawsuit against the company for potential securities fraud and prior disappointing financial results due to investor optimism about the company’s ongoing remediation efforts at a troubled manufacturing facility. Viatris (VTRS) stock increased by 0.13% despite a class action lawsuit alleging securities fraud against the company, which followed disappointing financial results and lowered guidance for 2025; the slight rise may result from market correction or investor sentiment anticipating a resolution to ongoing issues. Viatris (VTRS) stock rose 0.13% following news of a class action securities lawsuit against the company, which may have led to investor optimism about a potential recovery for those affected by the alleged securities fraud and subsequent stock price decline.
	2025-04-17	+2.3 %
The article discusses a securities class action lawsuit against Viatris Inc. (VTRS) related to undisclosed material information during a specific class period, while mentioning that the stock rose 2.3% overnight. The stock increase could be attributed to investor optimism or market speculation following the announcement of the lawsuit, as well as potential recovery in investor sentiment after a recent dip due to disappointing financial guidance. Viatris (VTRS) stock rose by 2.3% despite a class action lawsuit being filed against the company for alleged securities fraud and its recent reporting of disappointing financial results and lowered guidance, possibly due to market reactions and investor sentiment shifting positively following the announcement of progress in remediation efforts at a manufacturing facility. Viatris (VTRS) stock rose 2.3% following the announcement of an upcoming class action lawsuit related to investor losses from the company's recent financial disclosures and FDA inspection outcomes, indicating potential investor optimism or response to legal actions. Viatris Inc. (VTRS) stock rose 2.3% despite facing a lawsuit for potential securities law violations related to misleading statements about the operational status of its facilities, likely due to investor speculation or confidence in the company's ability to navigate legal challenges and improve its situation following regulatory issues.
	2025-04-16	-1.2 %
Viatris (VTRS) stock decreased by 1.2% following news about a class action lawsuit regarding allegations of misleading investors about the impact of a failed inspection at its Indore, India facility, which resulted in an FDA warning letter and import alert. Viatris (VTRS) stock fell 1.2% following a string of negative reports, including missing financial estimates and providing lower guidance for 2025, alongside concerns regarding regulatory issues at a manufacturing facility in India. Viatris (VTRS) stock fell by 1.2% following the announcement of a securities class action lawsuit against the company for failing to disclose material information, which was exacerbated by disappointing financial guidance attributed to regulatory issues, leading to a drop in share price from $11.24 to $9.53 after the news was released.
	2025-04-15	-1.97 %
The article discusses a decline in Viatris Inc. (VTRS) stock by 1.97% following revelations of an FDA warning letter regarding the company's Indore, India facility and disappointing financial guidance for fiscal 2025, which raised concerns over the company's operational stability. Viatris (VTRS) stock dropped by 1.97% following the announcement of a securities class action lawsuit that alleges the company misled investors regarding the impact of a failed inspection at its Indore, India facility and subsequent disappointing financial guidance due to this situation. The Viatris (VTRS) stock fell by 1.97% largely due to a class action lawsuit alleging that the company and its executives misled investors regarding the serious financial impacts from a failed FDA inspection at its Indore facility, which negatively affected its revenue outlook and growth expectations. Viatris Inc. (VTRS) stock fell by 1.97% following the announcement of a lawsuit alleging potential violations of federal securities laws due to the company downplaying the significant impact of a failed FDA inspection at its Indore, India facility, which is expected to lower revenue and earnings substantially.
	2025-04-14	+1.19 %
Viatris Inc. (NASDAQ:VTRS) stock rose by 1.19% as investors shift focus to defensive healthcare stocks amid recession and trade war concerns, bolstered by positive growth prospects in the company’s development of generic weight loss drugs and its significant revenue generation. The article discusses Viatris Inc. (VTRS) in the context of a list of top healthcare stocks recommended by billionaire David Einhorn, noting that VTRS stock increased by 1.19% likely due to its positive positioning among these recommended investments.
	2025-04-11	+3.86 %
Viatris (VTRS) stock rose 3.86% amidst ongoing litigation over potential federal securities law violations related to misstatements about its facility conditions and their impact on financial results, possibly reflecting investor optimism about navigating the legal challenges. Viatris (VTRS) stock increased by 3.86% in response to investor sentiment surrounding the upcoming annual meeting and concerns over recent dilutive financing actions taken by the board, which may have motivated the stock price movement as shareholders reacted to ongoing governance issues and the company's direction. Viatris (VTRS) stock rose by 3.86% following a class action lawsuit announcement related to misleading statements about the company's financial impact from a FDA warning on its Indore facility, suggesting potential investor recovery options might be driving market optimism.
	2025-04-10	-6.8 %
Viatris (VTRS) stock experienced a 6.8% decline following news of a class action securities lawsuit related to alleged securities fraud concerning the misrepresentation of regulatory issues with the company's Indore, India facility, which significantly impacted its financial guidance and investor confidence.
	2025-04-09	+5.84 %
Viatris (VTRS) stock rose 5.84%, possibly due to speculation or investor optimism despite a recently filed lawsuit alleging securities fraud against the company and senior executives, which indicates ongoing legal and financial challenges following an FDA inspection that significantly impacted its operations. Viatris (VTRS) stock experienced a 5.84% increase due to a potential rebound from its recent decline following disappointing earnings and guidance related to regulatory issues at its Indore facility, as investors may be anticipating a resolution or improvement in circumstances surrounding the FDA warning letter. The article discusses an investigation by Faruqi & Faruqi LLP into potential securities law violations by Viatris, Inc. amidst disappointing financial guidance and a significant stock price drop; however, despite this context, Viatris' stock rose by 5.84% last night, potentially due to market recovery, investor speculation, or short-term positive news influencing trading sentiment after a recent decline. Viatris (VTRS) stock rose by 5.84% due to shareholder interest stemming from a notice about a class action lawsuit related to misleading information regarding the company's operations and a subsequent decline in stock price that investors may now seek to recover from. Viatris (VTRS) stock experienced a 5.84% increase, likely due to investors reacting to upcoming legal proceedings related to a securities class action lawsuit, which may have led to optimism after the stock previously dropped significantly following disappointing earnings guidance.
	2025-04-07	-0.13 %
Viatris (VTRS) stock experienced a slight decline of 0.13% following the announcement of a class action lawsuit alleging securities fraud against the company and disappointing financial results reported in February. The stock's decline can be attributed to the negative implications of the class action lawsuit and missed financial expectations, coupled with lower-than-expected guidance for 2025. Viatris Inc. (VTRS) shares declined by 0.13% amid the announcement of a lawsuit against the company for potential federal securities law violations related to the negative impact of a failed FDA inspection at its Indore facility, which has significantly affected its financial outlook and operations. Viatris (VTRS) stock fell by 0.13% amid ongoing investigations into potential securities fraud and disappointing financial results for 2024, which included lower-than-expected guidance for 2025 and remediation updates for a manufacturing facility impacted by FDA warnings. Viatris (VTRS) stock has declined due to a class action lawsuit stemming from allegations that the company misled investors about the impact of a failed FDA inspection of its Indore, India facility, which led to disappointing financial results.
	2025-04-04	-6.62 %
Viatris (VTRS) stock fell by 6.62% due to negative investor sentiment following the announcement of a class action lawsuit linked to misleading information regarding the failed FDA inspection of its Indore, India facility, as well as disappointing financial guidance attributed to the impact of the inspection warning letter.
	2025-03-31	+0.35 %
Opus Genetics, Inc. has announced significant advancements in its gene therapy programs and financial stability after raising $21.5 million, which has positively impacted its stock performance, contributing to a 0.35% increase in Viatris (VTRS) stock likely due to investor confidence from the company's promising pipeline and strategic actions.
	2025-03-27	-1.34 %
Viatris (VTRS) stock fell by 1.34% as part of the ongoing fallout from a significant decline in its stock price following disappointing fourth quarter and full year 2024 financial results, lower-than-expected guidance for 2025, and concerns related to its manufacturing facility in India, which led to an investigation for potential securities fraud. Viatris (VTRS) stock fell by 1.34% amid an ongoing investigation by Rosen Law Firm into potential misleading business information provided by the company, which first triggered a larger drop of 15.2% following the announcement of a warning letter from the FDA that could negatively impact its revenues by approximately $500 million in 2025.
	2025-03-21	-3.07 %
Viatris (VTRS) stock fell by -3.07% due to shareholder concerns over the company's strategic missteps and governance failures exemplified by a recent dilutive financing that undermines existing stockholder interests, as highlighted by the Restore Value Slate's push for new board leadership ahead of the upcoming Annual Meeting.
	2025-03-20	+0.21 %
The article discusses an investigation initiated by Rosen Law Firm into potential securities claims against Viatris Inc. (NASDAQ: VTRS) due to allegations of misleading business information which may have impacted shareholder value, following a significant drop in stock price earlier this year. The slight increase of 0.21% in Viatris (VTRS) stock could be attributed to a potential stabilization in market sentiment as investors weigh the ongoing legal developments and the company's adjustments in response to regulatory challenges, despite previous declines following the FDA warnings.
	2025-03-19	-1.05 %
The article discusses that Viatris (VTRS) stock experienced a decline of 1.05% following an investigation announcement by Faruqi & Faruqi, LLP, after the company reported disappointing fourth-quarter financial results and lower-than-expected guidance for 2025, alongside ongoing remediation issues at a manufacturing facility.
	2025-03-05	+1.17 %
The article reports that Viatris (VTRS) stock experienced a 1.17% increase following a significant decline after disappointing financial results and lower guidance, as investors may be reassessing the company's potential recovery, particularly in light of ongoing remediation efforts at its manufacturing facility in India. Viatris (VTRS) stock rose by 1.17% likely due to positive market sentiment surrounding the pharmaceutical sector's potential growth from upcoming biosimilars, despite concerns over the impact of steep US tariffs on drug prices and patient access.
	2025-02-28	-3.15 %
Viatris (VTRS) stock fell by 3.15% due to concerns surrounding its recent agreements for developing cenerimod, a new drug candidate for autoimmune diseases, which may have uncertainties related to regulatory approvals and market potential.
	2025-02-27	-15.21 %
Viatris (VTRS) stock experienced a significant decline of -15.21%, primarily due to disappointing earnings results and heightened investor concerns about future growth prospects amid competitive pressures and market volatility. The article discusses the significant 15.21% decline in Viatris (VTRS) stock, likely attributed to negative investor sentiment amidst broader market volatility and uncertainties impacting the healthcare sector.
	2025-01-16	-0.44 %
Viatris Inc. (NASDAQ:VTRS) saw a 2.82% decline in its stock price, closing at $11.39, due to investor sell-off triggered by analyst comments about the stock entering oversold territory, compounded by negative sentiment surrounding the planned closure of its manufacturing plant in Ireland.
	2025-01-06	-2.69 %
Viatris (VTRS) stock went down by -2.69% likely due to concerns surrounding medication shortages and regulatory challenges impacting the pharmaceutical sector, particularly in the diabetes treatment market.
	2024-12-24	-0.72 %
Viatris (VTRS) stock fell by 0.72% amid scrutiny over a judge’s financial ties to the healthcare industry, raising concerns about potential conflicts of interest in a high-profile case involving healthcare criticism. The decline is likely influenced by the controversy surrounding the judge's investments, reflecting broader concerns about integrity and the healthcare sector. Viatris (VTRS) stock declined by 0.72% due to concerns over potential conflicts of interest involving the judge overseeing a high-profile case related to the shooting of UnitedHealthcare’s CEO, which has sparked scrutiny of the pharmaceutical industry.
	2024-11-29	-0.98 %
Viatris (VTRS) stock experienced a decline of 0.98% due to a challenging market environment and competition from other pharmaceutical companies, as highlighted by comparative analyses between Revance Therapeutics and AstraZeneca, where the latter showed stronger revenues and earnings.
	2024-11-07	+13.52 %
Viatris (VTRS) stock surged by 13.52% due to positive market sentiment and investor confidence amidst broader stock market fluctuations and forthcoming corporate developments. The increase in Viatris stock can be attributed to favorable market perceptions and potential growth factors regarding the company's operations and strategic direction.
	2024-10-28	+2.8 %
Viatris (VTRS) stock rose 2.8% due to factors such as strong institutional ownership indicating confidence from large investors, and its collaboration with Revance Therapeutics, which is advancing in various drug developments, potentially enhancing future growth prospects.